Teladoc shares plunged about 19.8% in pre-open trading after the company disclosed its second-quarter 2026 results following Wednesday's market close. The virtual care provider reported Q2 revenue of $606.9 million, below an analyst consensus near $615 million and representing a 4% decline from the same period a year earlier.
On the profitability side, Teladoc posted adjusted earnings per share of -$0.21, which beat the -$0.25 estimate. That bottom-line outperformance did little to counter investor concern over the top-line shortfall and the company's softer forward outlook.
The largest weakness came from the BetterHelp segment. BetterHelp revenue declined 12% year-over-year to $212.6 million as the pace of cash-pay user departures accelerated in late May and June. Management said this deterioration in cash-pay behavior was a primary driver of the overall revenue miss.
Looking ahead, Teladoc guided third-quarter revenue to a range of $569 million to $609 million, well under a Wall Street expectation of roughly $629 million. The company also narrowed and lowered its full-year 2026 revenue guidance to a range of $2.36 billion to $2.45 billion, down from a prior outlook of $2.48 billion to $2.58 billion - a reduction of approximately 5% from the earlier midpoint.
CEO Chuck Divita commented that demand for insurance-covered services remains strong, but that provider capacity constraints are limiting the company's ability to convert that demand into near-term revenue. In other words, Teladoc says more insured patients want services than the company can immediately serve because of limitations on provider availability.
Insider activity has offered no visible counterweight to investor concerns: in the past six months, all reported insider transactions were open-market sales; no insider purchases were recorded. Analysts' median price target, near $7, was already below the pre-earnings trading level.
The broader market environment provided additional headwinds. The S&P 500 fell sharply on July 29 after the Federal Reserve left interest rates unchanged but did not calm market nerves, while 30-year Treasury yields surged to their highest level in nearly two decades. That combination helped produce a risk-off tone heading into Thursday's pre-market session.
The convergence of a revenue miss, a marked reduction in guidance, structural challenges within the consumer-facing BetterHelp business, and a cautious macro backdrop pushed Teladoc shares to approximately $7.36 in pre-market trading. That price sits close to the lower end of the company's 52-week range of $4.40 to $9.89 as investors reassess the firm's near-term growth trajectory.